-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O3b569d55dxkmcJOp/HIAh1pEhFKmLRLgoHC5E8q4523ls21bGfNLds/CT0Gy6rs +0dly+aSHSCD5gJVjwrUzg== 0000930413-07-006473.txt : 20070806 0000930413-07-006473.hdr.sgml : 20070806 20070806171101 ACCESSION NUMBER: 0000930413-07-006473 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070806 DATE AS OF CHANGE: 20070806 GROUP MEMBERS: DR. JEFFREY R. JAY, M.D. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KERYX BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001114220 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134087132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-78786 FILM NUMBER: 071028657 BUSINESS ADDRESS: STREET 1: 750 LEXINGTON AVENUE STREET 2: . CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-531-5965 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREAT POINT PARTNERS LLC CENTRAL INDEX KEY: 0001281446 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 2 PICKWICK PLAZA STREET 2: STE 450 CITY: GREENWICH STATE: CT ZIP: 06830 SC 13G 1 c49742_sc13g.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

 
OMB APPROVAL
 
          OMB Number: 3235-0145
          Expires: February 28, 2009     
Estimated average burden
hours per response 10.4

 

Keryx Biopharmaceuticals, Inc.
(Name of Issuer)
 
 
Common Stock
(Title of Class of Securities)
 
 
192515101
(CUSIP Number)
 
 
July 25, 2007
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o     Rule 13d-1(b)

x    Rule 13d-1(c)

o     Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No.     192515101     
13G
Page 2 of 8 Pages          

 

     1.           NAMES OF REPORTING PERSONS
  Great Point Partners, LLC
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
  37-1475292    
       
     2.           CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)               o    
 
  (b)               o    
 

 
     3.           SEC USE ONLY    
 
 

 
     4.           CITIZENSHIP OR PLACE OF ORGANIZATION
  USA    
       
NUMBER OF SHARES 5.      SOLE VOTING POWER
BENEFICIALLY                                                                                  0
OWNED BY EACH
6. SHARED VOTING POWER
REPORTING PERSON
                                                                                  2,375,400
WITH
7. SOLE DISPOSITIVE POWER
                                                                                     0
    8. SHARED DISPOSITIVE POWER
                                                                                     2,375,400
       
     9.           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                     2,375,400    
       
     10.           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
  SHARES (See Instructions)                                                                                                     o
 
     11.           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
                     5.45%    
       
     12.           TYPE OF REPORTING PERSON (See Instructions)
                     OO    

CUSIP No.     192515101     
13G
Page 3 of 8 Pages          

 

     1.           NAMES OF REPORTING PERSONS
  Dr. Jeffrey R. Jay, M.D.
  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
       
       
     2.           CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)               o    
 
  (b)               o    
 

 
     3.           SEC USE ONLY    
 
 

 
     4.           CITIZENSHIP OR PLACE OF ORGANIZATION
  USA    
       
NUMBER OF SHARES 5.      SOLE VOTING POWER
BENEFICIALLY                                                                                  0
OWNED BY EACH
6. SHARED VOTING POWER
REPORTING PERSON
                                                                                  2,375,400
WITH
7. SOLE DISPOSITIVE POWER
                                                                                     0
    8. SHARED DISPOSITIVE POWER
                                                                                     2,375,400
       
     9.           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                     2,375,400    
       
     10.           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
  SHARES (See Instructions)                                                                                                     o
 
     11.           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
                     5.45%    
       
     12.           TYPE OF REPORTING PERSON (See Instructions)
                     IN    

CUSIP No.     192515101     
13G
Page 4 of 8 Pages          

 

     Item 1.

                          (a)          

Name of Issuer
 
   

Keryx Biopharmaceuticals, Inc.
 
  (b)

Address of Issuer’s Principal Executive Offices

750 Lexington Avenue New York, NY 10022

     Item 2.

                          (a)           Name of Person Filing
     
                   Great Point Partners, LLC
               Dr. Jeffrey R. Jay, M.D.
     
  The Reporting Persons have entered into a Joint Filing Agreement, dated August 6, 2007, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
   
  (b)

Address of Principal Business Office, or if none, Residence
 
   

The address of the principal business office of each of the Reporting Persons is
 
                   165 Mason Street, 3rd Floor
               Greenwich, CT 06830 
     
  (c) Citizenship
     
  Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States.
     
  (d)

Title of Class of Securities Common Stock
 
  (e)

CUSIP Number

192515101
 
     Item 3. If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the
                         person filing is a:
   
                        Not Applicable.
   

                          (a)    o     

Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
 
  (b)    o     

Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
 
  (c)    o     

Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).
 
  (d)    o     

Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 
  (e)    o     

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
 

CUSIP No.     192515101     
13G
Page 5 of 8 Pages          

 

                          (f)    o     

An employee benefit plan or endowment fund in accordance with §240.13d- 1(b)(1)(ii)(F).
 
  (g)   o      

A parent holding company or control person in accordance with §240.13d- 1(b)(1)(ii)(G).
 
  (h)   o     

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
 
  (i)    o     

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
 
  (j)    o     

Group, in accordance with §240.13d-1(b)(1)(ii)(J).
 
     Item 4.               Ownership

Great Point Partners, LLC (“Great Point”) is the investment manager of Biomedical Value Fund, L.P. (“BVF”), and by virtue of such status may be deemed to be the beneficial owner of the 1,282,716 shares of Common Stock of the Issuer owned by BVF (the “BVF Shares”). Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Great Point is the investment manager of Biomedical Offshore Value Fund, Ltd. (“BOVF”), and by virtue of such status may be deemed to be the beneficial owner of the 1,092,684 shares of Common Stock of the Issuer owned by BOVF (the “BOVF Shares”). Dr. Jay, as senior managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Great Point and Dr. Jay disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interest.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. Great Point Partners, LLC
   
(a)           Amount beneficially owned: 2,375,400
   
(b) Percent of class: 5.45%.
   
(c) Number of shares as to which the person has:
   
  (i)           Sole power to vote or to direct the vote: - 0 -
     
  (ii) Shared power to vote or to direct the vote: 2,375,400
     
  (iii) Sole power to dispose or to direct the disposition of: - 0 -.
     
  (iv) Shared power to dispose or to direct the disposition of: 2,375,400
     
2. Dr. Jeffrey R. Jay, M.D.
   
(a) Amount beneficially owned: 2,375,400
   
(b) Percent of class: 5.45%.
   
(c) Number of shares as to which the person has:

CUSIP No.     192515101     
13G
Page 6 of 8 Pages          

 

(i)          

Sole power to vote or to direct the vote: - 0 -
 
(ii)

Shared power to vote or to direct the vote: 2,375,400
 
(iii)

Sole power to dispose or to direct the disposition of: - 0 -
 
(iv)

Shared power to dispose or to direct the disposition of: 2,375,400
 
  Item 5. Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the
beneficial owner of more than five percent of the class of securities, check the following [    ].
     
   Item 6. Ownership of More than Five Percent on Behalf of Another Person:
                           
    See item 4.
     
  Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being
    Reported on by the Parent Holding Company
     
    Not Applicable.
     
  Item 8. Identification and Classification of Members of the Group
     
    Not Applicable.
     
  Item 9. Notice of Dissolution of Group
     
    Not Applicable.
     
  Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

 

 

CUSIP No.     192515101     
13G
Page 7 of 8 Pages          

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 6, 2007

GREAT POINT PARTNERS, LLC
   
By: 
 /s/ Dr. Jeffrey R. Jay, M.D.                                        
 
Dr. Jeffrey R. Jay, M.D.,
    as senior managing member
   
/s/ Dr. Jeffrey R. Jay, M.D.
DR. JEFFREY R. JAY, M.D.

CUSIP No.     192515101     
13G
Page 8 of 8 Pages          

 

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

 

The undersigned hereby agree as follows:

          (i)           Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

          (ii)          Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: August 6, 2007

GREAT POINT PARTNERS, LLC
     
By: 
 /s/ Dr. Jeffrey R. Jay, M.D.                                        
 
Dr. Jeffrey R. Jay, M.D.,
 
    as senior managing member  
     
/s/ Dr. Jeffrey R. Jay, M.D.           
DR. JEFFREY R. JAY, M.D.

-----END PRIVACY-ENHANCED MESSAGE-----